FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

• Published in: Journal for immunotherapy of cancer 2022-11, Vol.10 (11), p.e005780
• Main Authors: Choueiri, Toni K, Kluger, Harriet, George, Saby, Tykodi, Scott S, Kuzel, Timothy M, Perets, Ruth, Nair, Suresh, Procopio, Giuseppe, Carducci, Michael A, Castonguay, Vincent, Folefac, Edmund, Lee, Chung-Han, Hotte, Sebastien J., Miller, Wilson H, Saggi, Shruti Shally, Lee, Chung-Wei, Desilva, Heshani, Bhagavatheeswaran, Prabhu, Motzer, Robert J, Escudier, Bernard
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols - adverse effects; B7-H1 Antigen - therapeutic use; Cancer; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - pathology; Clinical/Translational Cancer Immunotherapy; Enrollments; FDA approval; Humans; Immunotherapy; Ipilimumab - therapeutic use; Kidney cancer; kidney neoplasms; Kidney Neoplasms - drug therapy; Kidney Neoplasms - pathology; Metastasis; Monoclonal antibodies; Nivolumab - therapeutic use; Oncology; Patients; Targeted cancer therapy; Treatment Outcome
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2022-005780

BackgroundThe role and sequencing of combination immuno-oncology (IO) therapy following progression on or after first-line IO therapy has not been well-established. The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program is an open-label, phase 2 platform trial designed to evaluate multiple IO combinations in patients with advanced renal cell carcinoma (aRCC) who progressed during or after prior IO therapy. Here, we describe the results for patients treated with nivolumab plus ipilimumab. For enrollment in track 2 (reported here), patients with histologically confirmed clear cell aRCC, Karnofsky performance status ≥70%, and life expectancy ≥3 months who had previously progressed after IO (anti-programmed death 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4)) therapy were eligible. Previous treatment with anti-CTLA-4 therapy plus anti-PD-1/PD-L1 therapy precluded eligibility for enrollment in the nivolumab plus ipilimumab arm. Patients were treated with nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for four doses, followed by nivolumab 480 mg every 4 weeks for up to 2 years or until progression, toxicity, or protocol-specified discontinuation. The primary outcome measures were objective response rate (ORR), duration of response (DOR), and progression-free survival (PFS) rate at 24 weeks. Secondary outcomes were safety and tolerability up to 2 years. Overall survival (OS) was a tertiary/exploratory endpoint. Overall, 46 patients were included with a median follow-up of 33.8 months. The ORR was 17.4% (95% CI, 7.8 to 31.4) with eight (17.4%) patients achieving partial response. Stable disease was achieved in 19 (41.3%) patients, while 14 (30.4%) had progressive disease. Median DOR (range) was 16.4 (2.1+ to 27.0+) months. The PFS rate at 24 weeks was 43.2%, and median OS was 23.8 (95% CI, 13.2 to not reached) months. Grade 3–4 immune-mediated adverse events were reported in seven (15.2%) patients. No treatment-related deaths were reported. Patients with aRCC treated with nivolumab plus ipilimumab may derive durable clinical benefit after progression on previous IO therapies, including heavily pretreated patients, with a manageable safety profile that was consistent with previously published safety outcomes. These outcomes contribute to the knowledge of optimal sequencing of IO therapies for patients with aRCC with high unmet needs.Trial registration number NCT0299